본문으로 건너뛰기
← 뒤로

siRNA-based Nanocarriers for Targeted Therapy in Prostate Cancer: Implications for Male Fertility Preservation.

1/5 보강
Drug discovery today 📖 저널 OA 10.3% 2023: 0/1 OA 2024: 0/1 OA 2025: 2/8 OA 2026: 1/19 OA 2023~2026 2025 Vol.30(12) p. 104543
Retraction 확인
출처

Jangde KK, Sharma R, Mishra DK, Mishra PK

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Prostate cancer (PC), a significant global health burden, is further complicated by therapeutic resistance, systemic toxicity, and adverse effects on male fertility associated with conventional treatm

이 논문을 인용하기

↓ .bib ↓ .ris
APA Jangde KK, Sharma R, et al. (2025). siRNA-based Nanocarriers for Targeted Therapy in Prostate Cancer: Implications for Male Fertility Preservation.. Drug discovery today, 30(12), 104543. https://doi.org/10.1016/j.drudis.2025.104543
MLA Jangde KK, et al.. "siRNA-based Nanocarriers for Targeted Therapy in Prostate Cancer: Implications for Male Fertility Preservation.." Drug discovery today, vol. 30, no. 12, 2025, pp. 104543.
PMID 41241375 ↗

Abstract

Prostate cancer (PC), a significant global health burden, is further complicated by therapeutic resistance, systemic toxicity, and adverse effects on male fertility associated with conventional treatments. Small interfering RNA (siRNA)-based therapeutics offer molecular precision in oncogene silencing and tumor-promoting pathways. However, their clinical translation is constrained by challenges related to stability, delivery, and cellular uptake. Nanocarriers, including lipid-based, exosome-based, and other polymeric-based systems, could enhance stability, specificity, and efficacy. In this review, we highlight biomarker-targeted siRNA codelivery for PC, considering reproductive health and translational barriers, highlighting the future of fertility-preserving and quality of life-oriented therapies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반